摘要
探究阿格列汀联合二甲双胍对治疗2型糖尿病(T2DM)合并非酒精性脂肪肝(NAFLD)的疗效及安全性。选取2018年6月至2020年3月亳州市人民医院收治的80例初发T2DM且合并NAFLD患者为研究对象,随机均分为两组,对照组采用二甲双胍药物治疗,治疗组采用阿格列汀联合二甲双胍治疗,共20 w。观察两组治疗后肝功能,血脂代谢,糖代谢、胰岛β细胞功能及血清因子水平等指标的临床疗效及不良反应情况。治疗前两组患者相关指标均无明显差异(P>0.05);治疗后,治疗组的天冬氨酸氨基移酶(AST)、丙氨酸氨基转移酶(ALT)、γ-氨酰转肽酶(GGT)等肝功能指标水平均明显低于对照组(P<0.05);两组患者的总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白(LDL-C)较治疗前均显著下降(P<0.05);治疗组的身体指数(BMI)、空腹血糖(FPG)、餐后2h血糖(2h PG)、糖化血红蛋白(HbA1c)、胰岛素抵抗指数(HOMA-IR)相比于对照组均显著下降(P<0.05);β细胞功能指数(HOMA-β)明显升高,差异显著(P<0.05);治疗组FGF21、HsCRP水平显著低于对照组(P<0.05),两组的不良反应发生率无统计学差异(P>0.05)。阿格列汀联合二甲双胍治疗T2DM合并NAFLD的临床疗效明确,能有效降低血糖,改善血脂水平,降低肝酶、减轻肝细胞损伤,安全性较高。
To explore the efficacy and safety of alogliptin combined with metformin in the treatment of type 2 diabetes(T2 DM)combined with non-alcoholic fatty liver(NAFLD),80 patients with initial T2 DM and NAFLD who were admitted to the authors’hospital from June 2018 to March 2020 were selected as the research objects,and they were randomly divided into two groups.The control group was treated with metformin and the treatment group was treated with alogliptin combined with metformin treatment.The clinical efficacy and adverse reactions of liver function,blood lipid metabolism,glucose metabolism,pancreaticβ-cell function and serum factor levels after treatment in the two groups were observed.There was no significant difference in relevant indicators between the two groups before treatment(P>0.05).After treatment,aspartate aminotransferase(AST),alanine aminotransferase(ALT),andγ-glutamine,acyltranspeptidase(GGT)in the treatment group were significantly lower than those of the control group(P<0.05).After treatment,the total cholesterol(TC),triacylglycerol(TG),low-density cholesterol(LDL-C)and other blood lipid metabolism indexes of the two groups of patients were significantly lower than before treatment.The body index(BMI),fasting blood glucose(FPG),2 h postprandial blood glucose(2 h PG),glycosylated hemoglobin(HbA1 c),and insulin resistance index(HOMA-IR)of the treatment group were significantly lower than those of the control group.βcells functional index(HOMA-β)was significantly increased,with a significant difference(P<0.05)between the two groups.There was no statistical difference in the incidence of adverse reactions between the two groups(P>0.05).The clinical efficacy of alogliptin combined with metformin in the treatment of T2 DM combined with NAFLD is obvious.It can effectively reduce blood sugar without increasing the risk of hypoglycemia.It has high safety and has clinical application value.
作者
石方方
瞿香坤
周玉森
李新杰
武玮
孙杰
SHI Fang-fang;QU Xiang-kun;ZHOU Yu-sen;LI Xin-jie;WU Wei;SUN Jie(Department of Endocrinology,Bozhou Peopled Hospital,Bozhou Clinical College of Anhui Medical University,Bozhou 236800,China;Department of Respiratory Medicine and Critical Care Medicine,Bozhou Peopled Hospital,Anhui Medical University,Bozhou Medical College,Bozhou 236800,China)
出处
《药物生物技术》
CAS
2021年第5期501-504,共4页
Pharmaceutical Biotechnology
基金
安徽省科技攻关计划资助项目(No1604a0802091)
亳州市科技局重点研发计划(No.BZZC2019015)。
